Alpha 2.0
Login Register
» Authors » Christopher Zacker

Christopher Zacker

Explore the profile of Christopher Zacker including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 396
Followers 0
Related Specialties
Pharmacology
Pharmacy
Health Services
Top 10 Co-Authors
Khalid M Kamal
Rahul Sasane
Kristin Richards
Darius Lakdawalla
Jenifer Wogen
Daniel A Belletti
Michael Johnsrud
Ahva Shahabi
Laura Dick
Keyuri Adhikari
Published In
J Manag Care Spec Pharm
Res Social Adm Pharm
Am J Manag Care
Clinicoecon Outcomes Res
Am J Hypertens
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence
Adhikari K, Kamal K, Jeun K, Nolfi D, Ashraf M, Zacker C
Clinicoecon Outcomes Res . 2024 Sep; 16:621-645. PMID: 39257455
Background: Schizophrenia is a complex, chronic mental health disorder that confers a substantial disease burden globally. Oral antipsychotic treatments (OATs) are the mainstay for treating early and advanced stages of...
2.
Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation
Richards K, Johnsrud M, Zacker C, Sasane R
Community Ment Health J . 2024 Sep; 61(3):432-439. PMID: 39240484
Researchers have used elements of administrative healthcare claims data (e.g., diagnosis codes and medications) to calculate rates of extrapyramidal symptoms (EPS) in patients with schizophrenia who utilize second-generation antipsychotics (SGAs)....
3.
Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia
Zacker C, Puckett J, Kamal-Bahl S
Clinicoecon Outcomes Res . 2024 Aug; 16:567-579. PMID: 39161925
Purpose: Little is known about adherence to and discontinuation of newly initiated oral antipsychotics (OAPs) as well as associated factors among Medicare beneficiaries with schizophrenia. This study aimed to examine...
4.
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study
Fee R, Webb N, Dick L, White J, Essoi B, Walker V, et al.
J Manag Care Spec Pharm . 2024 May; 30(7):698-709. PMID: 38717043
Background: Antipsychotic switching is frequent in schizophrenia and is associated with poor clinical outcomes, increased health care resource utilization (HCRU), and increased health care costs. Research describing the reasons for...
5.
Patterns of care and costs of switching oral antipsychotic medications in patients with schizophrenia initiating monotherapy treatment: A US claims analysis
Fee R, Webb N, Dick L, White J, Essoi B, Walker V, et al.
J Manag Care Spec Pharm . 2024 Apr; 30(6):560-571. PMID: 38591754
Background: Antipsychotic medications are the mainstay of schizophrenia therapy but may need to be changed over the course of a patient's illness to achieve the desired therapeutic goals or minimize...
6.
A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps
Jeun K, Kamal K, Adhikari K, Nolfi D, Ashraf M, Zacker C
J Manag Care Spec Pharm . 2024 Feb; 30(2):183-199. PMID: 38308625
Background: Schizophrenia is a chronic, relapsing, and burdensome psychiatric disorder affecting approximately 0.25%-0.6% of the US population. Oral antipsychotic treatment (OAT) remains the cornerstone for managing schizophrenia. However, nonadherence and...
7.
Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia
Richards K, Johnsrud M, Zacker C, Sasane R
Patient Prefer Adherence . 2024 Jan; 18:177-185. PMID: 38259956
Purpose: To examine 1-year persistence with oral atypical antipsychotics (OAAPs) for Medicaid patients with schizophrenia and assess the association between OAAP persistence and hospital and emergency department (ED) resource utilization....
8.
One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication
Richards K, Johnsrud M, Zacker C, Sasane R
Adm Policy Ment Health . 2023 Dec; 51(2):207-216. PMID: 38071724
Oral atypical antipsychotic (OAAP) medications are the most commonly prescribed treatment for the management of schizophrenia symptoms. This retrospective study, using Medicaid claims data (2016-2020), followed patients for 12 months...
9.
A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data
Slejko J, Rueda J, Trovato J, Gorman E, Betz G, Arcona S, et al.
J Manag Care Spec Pharm . 2019 Sep; 25(10):1125-1132. PMID: 31556821
Background: Understanding the real-world use of oral oncolytics is essential to assess drug effectiveness. Retrospective analyses using medical and pharmacy claims data allow observation of drug use patterns and health...
10.
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer
Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal A
J Manag Care Spec Pharm . 2019 Jul; 25(8):859-866. PMID: 31347980
Background: Discarding unused drugs after dose changes or discontinuation can significantly affect pharmacy budgets. This is especially concerning for expensive oncology agents. However, few economic studies account for drug wastage,...